Interferon Beta-1A
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
- Interferon Beta-1A
- Interferon beta-1a: From Relapsing-Remitting Multiple Sclerosis to Jeune Syndrome Situs Inversus
Interferon beta-1a: From Relapsing-Remitting Multiple Sclerosis to Jeune Syndrome Situs Inversus
One-Sentence Summary
Interferon beta-1a is an immunomodulatory biologic originally used to treat relapsing-remitting multiple sclerosis. The TxGNN model predicts it may be effective for Jeune syndrome situs inversus, but this is a computational prediction only, with 0 clinical trials and 0 relevant publications supporting it.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Relapsing-remitting multiple sclerosis |
| Predicted New Indication | Jeune syndrome situs inversus |
| TxGNN Prediction Score | 97.47% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 2 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, interferon beta-1a is an immunomodulatory biologic. Its efficacy in relapsing-remitting multiple sclerosis is established, but no mechanistic link to Jeune syndrome situs inversus has been identified.
Jeune syndrome (asphyxiating thoracic dystrophy) is a ciliopathy with skeletal and renal involvement. Interferon beta-1a's immunomodulatory activity has no evident relevance to this pathophysiology. The high TxGNN score (97.47%) reflects a knowledge-graph association only and is not supported by biological or clinical evidence. The other nine top-ranked predictions are likewise computational only and have no clinical trial or literature support. They include congenital craniofacial and cardiac malformations, chromosomal deletion syndromes, and rare ovarian neoplasms.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available for the predicted indication, Jeune syndrome situs inversus.
Literature retrieved for the fourth-ranked prediction (disorder of fucoglycosan synthesis) was reviewed. All of it concerns multiple sclerosis therapies (such as teriflunomide, alemtuzumab, and fingolimod) or unrelated topics (a COVID-19 guideline, Alzheimer's disease). These are false-positive matches and do not support any predicted new indication. They do give context on the original indication, including network meta-analyses of relapsing-remitting MS treatments.
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN13975P | Rebif Solution for Injection in Cartridge 44mcg/0.5ml | Injection, solution | Not available |
| SIN13974P | Rebif Solution for Injection in Cartridge 22mcg/0.5ml | Injection, solution | Not available |
Both registrations are valid single-ingredient products from Merck Serono S.p.A (Bari), in injectable form.
Safety Considerations
Drug Interactions: The interaction screening returned 100 interactions in total. The main ones noted are:
- Major: Bupropion
- Moderate (examples): acarbose, pioglitazone, rosiglitazone, clarithromycin, levofloxacin, minocycline, naltrexone, rosuvastatin, simvastatin, orlistat, and the anabolic steroids oxandrolone, oxymetholone and stanozolol
Please refer to the package insert for warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests only on a knowledge-graph score. There are no clinical trials or relevant publications, and no plausible mechanistic link between interferon beta-1a and Jeune syndrome situs inversus. Safety label information is also missing.
To proceed, the following is needed:
- Mechanism of action data for interferon beta-1a
- Package insert warnings and contraindications from the HSA
- A credible biological rationale linking interferon beta-1a to the predicted indication
- Preclinical or mechanistic studies, if the indication is to be pursued
- Review of lower-ranked predictions for any with stronger evidence, since none of the top 10 currently has supporting trials
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.